Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Mesoblast
ISIN US5907174016
|WKN A4004R
Market cap (in EUR)
1,662 m
Country
Australia
Sector
Healthcare
Overview
Description
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Australia
Financials
Key metrics
| Market capitalisation, EUR | 1,662 m |
| EPS, EUR | - |
| P/B ratio | 3.5 |
| P/E ratio | - |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | 16 m |
| Net income, EUR | -94 m |
| Profit margin | -593.92% |
What ETF is Mesoblast in?
There is 1 ETF which contains Mesoblast.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.06% | Equity United States Health Care Biotech | 47 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.